Keyphrases
Hepatocellular Carcinoma
100%
Sorafenib
100%
Sorafenib Treatment
100%
GIDEON
100%
Real-world Experience
100%
Child-Pugh A
80%
Median Overall Survival
40%
Time to Progression
40%
Overall Time
40%
Child-Pugh B
40%
Korean Patients
20%
Diarrhea
20%
Phase II Trial
20%
Safety Profile
20%
Daily Dose
20%
Clinical Setting
20%
Safety Analysis
20%
Survival Benefit
20%
Prospective Observational Study
20%
Treatment-related Adverse Events
20%
Drug Adverse Events
20%
Hepatocellular Carcinoma Patients
20%
Starting Dose
20%
B-group
20%
Electronic Version
20%
Therapeutic Decision-making
20%
Case Report Form
20%
Efficacy Data
20%
Treatment Emergent
20%
Safety Data
20%
Child-Pugh
20%
Child-Pugh Score
20%
Hand-foot Skin Reaction
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Sorafenib
100%
Adverse Event
33%
Overall Survival
33%
Diarrhea
16%
Observational Study
16%
Hand Foot Syndrome
16%